Madrigal Pharmaceuticals, Inc. (MDGL) earnings: date, estimates, results and stock reactions
Over the last 12 reports the stock moved 12.3% on average (either way), rising 5 times and falling 7. EPS beat estimates 8 of 11 times; revenue 7 of 10. Close before the report date to the first close after it (two trading sessions, covering before-the-open and after-the-close reports).
| Quarter | Reported | EPS | EPS estimate | EPS surprise | Revenue | Revenue estimate | Stock move |
|---|---|---|---|---|---|---|---|
| Q4 FY2026 | 2026-11-03 | 1.83 | -0.86 | +312.0% | 431.3M | 404.2M | -7.1% |
| Q3 FY2026 | 2026-07-30 | -1.99 | -2.68 | +25.7% | 364.3M | 352.1M | -14.5% |
| Q2 FY2026 | 2026-05-06 | -3.25 | -3.61 | +10.0% | 311.3M | 301.1M | +6.4% |
| Q1 FY2026 | 2026-02-19 | -2.57 | 0.04 | n/a | 321.1M | 312.5M | -11.5% |
| Q4 FY2025 | 2025-11-04 | -5.08 | -2.04 | -149.4% | 287.3M | 245.0M | +15.4% |
| Q3 FY2025 | 2025-08-05 | -1.90 | -3.48 | +45.4% | 212.8M | 243.5M | +8.3% |
| Q2 FY2025 | 2025-05-01 | -3.32 | -3.62 | +8.3% | 137.3M | 158.9M | -5.5% |
| Q1 FY2025 | 2025-02-26 | -2.71 | -4.32 | +37.3% | 103.3M | 97.8M | +8.5% |